Exelixis Wins Federal Circuit Appeal Affirming Key Cabozantinib Patent Validity Against MSN Laboratories

Executive Summary

On August 31, 2026, Exelixis, Inc. ($EXEL) filed a Current Report on Form 8-K under Item 8.01 (Other Events) disclosing a key legal victory at the U.S. Court of Appeals for the Federal Circuit in its patent infringement litigation against MSN Laboratories Private Limited (Exelixis, Inc. v. MSN Laboratories Private Limited et al., Appeal No. 25-1236).

---

Key Legal & Commercial Highlights

1. Affirmation of Patent Validity:
   • The Court of Appeals affirmed the judgment of the U.S. District Court for the District of Delaware, ruling that U.S. Patent Nos. 11,091,439, 11,091,440, and 11,098,015 are valid.
2. Generic Entry Barred Until at Least 2030:
   • Under the appellate decision, the effective date of any final FDA approval for MSN's Abbreviated New Drug Application (ANDA) cannot be earlier than January 15, 2030 (the expiration date of the '439, '440, and '015 patents).
3. Mooted Claims & Vacatur:
   • The Federal Circuit dismissed as moot MSN's appeal regarding U.S. Patent No. 11,298,349 (expiring February 10, 2032) and vacated the district court's decision on that patent.
4. Upcoming Trial in Late 2026:
   • Exelixis maintains separate ongoing litigation regarding U.S. Patent No. 12,128,039, which expires in February 2032, with a trial scheduled to commence in November 2026.

---

Market & Strategic Impact

• Revenue Protection: Securing patent protection through at least January 15, 2030 removes near-term generic risk from MSN Laboratories, preserving market exclusivity for Exelixis' core commercial franchise.
• Upside Exclusivity to 2032: The upcoming November 2026 trial on the '039 patent provides an avenue to extend generic exclusivity through February 2032.